Risk management plan (RMP): questions and answers
This page is intended to provide advice to Marketing Authorisation Holders of centrally authorised medicinal products about procedural and regulatory aspects to the Risk Management Plan (RMP) lifecycle during the post authorisation phase. It addresses the classification of changes to the RMP, submission requirements and aspects to be considered in the management of parallel procedures affecting RMP. Revised topics are marked 'New' or 'Rev.' upon publication.
A PDF version of the entire post-authorisation guidance is available:
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure (PDF/3.44 MB)
First published: 01/07/2009
Last updated: 17/12/2019
EMEA-H-19984/03 Rev. 84
European Medicines Agency post-authorisation procedural advice for users of the centralised procedure - track changes (PDF/2.89 MB)
First published: 09/12/2013
Last updated: 17/12/2019
EMEA-H-19984/03 Rev. 84
MAHs must in all cases comply with the requirements of Community legislation. Provisions that extend to Iceland, Liechtenstein and Norway by virtue of the European Economic Area agreement are outlined in the relevant sections of the text.
A new RMP or an update of the RMP, as applicable, may need to be submitted at any time during a product's lifecycle.
Since July 2012, all new marketing authorisations (MAs) applications should include an RMP. However, as the provision of an RMP was not mandatory before that date, there are still MAs for some centrally authorised products without an RMP. It should be noted, however, that for these products without RMP there are situations (e.g. new safety concerns, significant changes to the MA) that may trigger the need to introduce an RMP.For medicinal products with an RMP, whenever new data are provided as part of a regulatory application in the post-authorisation setting, the MAH should consider whether consequential significant changes to the RMP are needed. Should this be the case, a revised RMP should be included as part of the regulatory application as it is the responsibility of the MAH to update the RMP whenever new information is being received that have a significant impact on the content of the RMP.
An RMP update is expected to be submitted at any time when there is a change in the list of the safety concerns or when there is a new or a significant change in the existing additional pharmacovigilance or additional risk minimisation activities. For example, a change in study objectives, population, due date of final results, a due date for protocol submission for an imposed study, or addition of a new safety concern in the key messages of the educational materials would be expected to be reflected in an updated RMP with the procedure triggering those changes. The significant changes of the existing additional pharmacovigilance and risk minimisation activities may include removing such activities from the RMP.
An update of the RMP might also be considered when data submitted in the procedure results or is expected to result in changes of routine pharmacovigilance activities beyond adverse reaction reporting and signal detection activities, or of routine risk minimisation activities recommending specific clinical measures to address the risk. For example, an RMP update might be warranted with a significant change of the plans for annual enhanced safety surveillance (routine pharmacovigilance activity), or when monitoring of renal function is added as a recommendation in the Special warnings and precautions for use section 4.4 of the SmPC (routine risk minimisation activity). The need to update the plans to evaluate the effectiveness of risk minimisation activities should also be considered with such updates.
When an emerging safety issue is still under assessment (as defined in GVP Module VI), in particular in the context of a signal or potential risk that could be an important identified risk, an RMP update may be required if the emerging safety issue is confirmed and the important identified or potential risk requires to be added to the list of safety concerns in the RMP.
The need for an update to the RMP or a new RMP, including procedural aspects, should be discussed with the Agency, as appropriate, well in advance of the submission of an application, and in particular when involving a significant change to an existing marketing authorisation and/or parallel procedures warranting an RMP update.
It is expected that for RMP updates which are consequential to the data provided in a regulatory application, the updated RMP should be provided as part of the same application (see also Question 4 below). However, if an RMP needs to be updated outside any regulatory procedure, this RMP should be submitted as a stand-alone variation.
A stand-alone variation for updates of the RMP may be foreseen or requested by the Agency in particular in the following situations:
- In case of changes to the safety concerns outside another procedure; for instance, if interim results of a study assessed as a post-authorisation measure (PAM) lead to changes in the safety specifications (i.e. the need to add, delete or reclassify safety concerns);
- As a follow-up of a PSUR or signal procedure.
RMP updates cannot be accepted together with the PSURs of medicinal products (centrally and/or nationally authorised) subject to a PSUR EU single assessment (PSUSA), unless the PSUSA procedure includes only CAPs which are part of the same global MA (e.g. duplicate MAs). MAHs should update their RMP through another upcoming procedure affecting the RMP or alternatively, through a separate variation which can be submitted after finalisation of the PSUSA procedure;
- In case of proposed changes to already previously agreed category 3 studies in Part III.4.3 of the RMP. This applies also when the MAH has provided an updated / amended protocol that has been assessed via the PAM procedure and which has an impact on the description of the study in Part III.4.3.
If the MAH considers that no update of the RMP is warranted at the time of submission of a regulatory application following the assessment of the application, the PRAC/CHMP may or may not agree with the view that no RMP changes are warranted. If not agreed, the MAH will be requested to provide an updated RMP in response to a CHMP Request for Supplementary Information (RSI) during the procedure.
It is essential to always strive to conclude the RMP assessment during the procedure i.e. a final updated RMP version should be provided for agreement prior to the CHMP Opinion. However, if the PRAC/CHMP agrees that the requested update may not be possible during the procedure taking the procedural timelines into account, the RMP can instead be updated at the 'next regulatory opportunity', i.e. as part of the next application or as a stand-alone variation.
In this regards, if relatively minor RMP changes are requested by PRAC/CHMP for implementation at the 'next regulatory opportunity', the changes can be included as part of another appropriate regulatory procedure under a single scope (e.g. as part of a type IB variation or type II variation affecting the RMP without the need for an additional specific variation(s)) (see also Question 5 below). However, in the situation where additional data and significant further assessment is still necessary, this requires a separate type II variation regardless of whether it is submitted as a stand-alone variation application or part of a grouped application.
4.1. Consequential RMP updates
All RMP changes are in principle considered as changes to the MA and therefore require the submission of a specific variation. However, when the RMP updates are consequential to the data provided in an application, the updated RMP should be included as part of the same application. The latter is frequent for type II variations submitted under categories C.I.4 or C.I.6 when the product information is affected, type II variations under category C.I.13 when a final study report is provided without any impact on the product information, for line extension applications, renewals of MA and for PSURs when the proposed update is related to the data submitted in the PSUR.
In addition, in case changes to the conditions either proposed by the MAH or resulting from the assessment e.g. safety study in Annex II D or Annex II E or additional risk minimisation measures in Annex II D, the MAHs should also implement consequential changes to the RMP as part of the same application/procedure.
4.2. Variation classification categories for stand-alone RMP updates
Type II C.I.11.b
- Introduction of a new RMP outside another regulatory procedure.
- Addition, modification or deletion of safety concerns (identified risks, potential risks, missing information) not previously assessed and agreed by the EMA (e.g. with signals, PSURs).
- Changes to agreed post-authorisation studies in the RMP, if there is an impact on the description of the study (objectives as given in the summary table of on-going and planned additional pharmacovigilance activities, excluding changes to due dates) and/or to risk minimisation measures in the RMP not previously assessed and agreed by the EMA;
- Study objective: e.g. no more hypothesis testing.
- Study population: type or number, if it may restrict the objective; e.g. considerable sample size reduction; decrease in centres or geographical spread.
- Study design: e.g. follow-up type; passive versus patient diary.
Type IB category C.I.11.z
- Updates of RMPs not falling within the scope of type II variations (see above) are in principle type IB variations.
- Addition, modification or deletion of a safety concern (identified risks, potential risks, missing information) which has already been assessed and requested by the PRAC/CHMP in a previous procedure; i.e. the changes have already been formally assessed and agreed in principle as part of a previous procedure (e.g. assessment of signals, PSURs, variations, PAMs) by the PRAC/CHMP, although the agreement on the exact wording to be implemented in the RMP is still pending and further assessment is therefore required.
Note: In order for the implementation of pre-agreed RMP changes to be handled as a type IB variation, no additional data should be needed or submitted to support the proposes changes.
- Change to the final results due date i.e. the date for the provision of the final study report for category 1, 2 or 3 studies in the RMP and/or the Annex II, as relevant.
- Changes of a due date for protocol submission for an imposed study.
Note: Because no specific changes are identified by the variations classification guideline as falling by default into the type IB variation category, the above changes lead to such variation only when they constitute the reason for submitting the updated RMP. In case the MAH takes the opportunity to propose such changes with an RMP update undertaken for another reason (e.g. as part of a type II variation), these changes are accepted as minor and do not trigger additional variation scopes (please refer to Question 5 below).
Type IAIN category C.I.11 a)
- Implementation of changes to the conditions based on an exact wording agreed by PRAC/CHMP without any further changes, provided that no linguistic review of translations is required in case of simultaneous changes to the Annex II (i.e. deletion of information, changes to timelines are acceptable but not the implementation of new wording as such).
- Update of the RMP in response to a request following signal detection provided an exact wording agreed by PRAC/CHMP is implemented without further changes.
- Update of the RMP in response to a request following assessment of a protocol of a category 1,2 or 3 study provided an exact wording agreed by PRAC/CHMP is implemented without further changes.
Note: The changes to be implemented must already have been assessed by the Committee(s) in a previously concluded procedure; only the exact agreed wording is implemented, no additional changes are proposed and no further assessment is required.
However, it should be noted that it is rare that an exact wording is pre-agreed and therefore in most cases a type IB or type II variation will be required. Regardless, the MAH should always specify in the submission whether or not the proposed changes have already been assessed, and if so, as part of which procedure.
It is in principle acceptable to take the opportunity of a regulatory application (e.g. a type IB or type II variation) which warrants an update of the RMP to implement also:
- minor administrative changes to the RMP;
- template-related updates (e.g. from RMP template rev. 1 or rev. 2);
- updates of clinical / post-marketing data (e.g. exposure data and data coming from important clinical trials without impact on key safety information or final due dates);
- changes to category 4 studies listed in table III.4.4 (stated additional pharmacovigilance activities, also known as 'REC'= Recommendation) (only for RMPs using rev. 1 of the RMP template);
as long as the proposed changes are not affecting the summary of the safety concerns, the summary table of additional pharmacovigilance activities, the routine risk minimisation activities recommending specific clinical measures to address the risk or additional risk minimisation activities.
Further, in the event that relatively minor RMP changes are requested by PRAC/CHMP for implementation at the 'next regulatory opportunity', i.e. as part of the next application resulting in more substantial changes to the RMP (e.g. type IB variation, type II variation, line extension, renewal), these changes can be included as part of the next upcoming RMP update under a single scope i.e. without any need for an additional specific variation, unless there is a defined timeframe by when the update is requested and there is no other planned major RMP update in the same timeframe.
Each proposed 'major change' to the RMP triggers in principle its own type II variation scope.It should be noted that one specific type II variation is required for each scope even when submitted together with other major changes as part of a grouped variation application. The same rules apply to the grouping of major RMP changes as to the grouping of any other (non)clinical type II variations:
- changes meaningful to be reviewed simultaneously can be grouped;
- non-clinical and clinical safety changes are not accepted as part of the same grouping;
- and grouping should not delay the implementation of important changes (for instance a proposed extension of indication should not be grouped with safety variations).
With regard to multiple 'minor changes' which can be assessed as type IB variations if submitted on their own, these do not require a grouped application; instead it is acceptable to include these minor changes as part of one single type IB variation or type II variation without the triggering of additional type IB variation scopes i.e. any need for additional variations (see also Question 5 above).
The following cases are meant to illustrate how these rules would be applied for RMP updates:
Addition of a new Adverse Drug Reaction and a relevant warning to the SmPC via a type II variation C.I.4 with consequential update of the list of important identified risks in the RMP and submission of a final study report for a category 3 study in the RMP via a type II variation C.I.13 with consequential updates of the RMP (i.e. removal of the study from the Pharmacovigilance Plan). This can be submitted as a grouped application of 2 type II variations.
Submission of a final study report for a category 3 study via a type II variation C.I.13 with consequential updates of the RMP, and:
- Deletion of the category 3 study in the RMP – no need for separate variation since related to the main application;
- Addition of a safety concern in the RMP following a request from PRAC as part of a PSUR assessment – 1 (grouped) Type II category C.I.11.b if additional data are submitted and/or further significant assessment is required; no need for a separate variation otherwise as the change is implemented as part of a type II variation affecting the RMP;
- Changes to the due date for the provision of the final study report for a category 3 study in the RMP – no need for a separate variation as the change is implemented as part of a type II variation affecting the RMP;
- Update of the RMP with significant changes of the clinical trial exposure – can be implemented within the variation without the need for an additional variation.
Changes to the due date for the provision of the final study report for two category 3 studies in the RMP.
This can be submitted as a single type IB variation under category C.I.11.z.
On the other hand, a grouped application is generally not acceptable if it creates the risk of postponing the implementation of important safety information in the RMP:
- In case a type II variation is submitted under category C.I.6 (Extension of Indication), the RMP version submitted as part of this application should include changes that are consequential to the new data provided and the new proposed indication, and it can also include changes that have been previously assessed and agreed.As the procedure for an extension of indication application may take some months to finalise, other non-related changes that require assessment should not be included and/or grouped with an extension of indication application (e.g. the implementation of safety information should not be delayed).
There is only one approved RMP at any time for a medicinal product. Consequently, any time an updated RMP is approved as part of a procedure (e.g. variation, renewal, PSUR), this RMP becomes the approved RMP of the product, and any previous version becomes obsolete. Therefore, MAHs should carefully consider the planning of RMP submission, to make sure that the approved RMP always contains the most up-to-date information on the pharmacovigilance planning and risk minimisation measures.
Given the content-based requirements for RMP submission, it is expected that there will be only few procedures where an RMP update should be included. The MAH should consider whether an RMP is really required with the procedure that is in preparation for submission. Early discussion with the regulators should facilitate the submission, to avoid unnecessary RMP submissions and assessment; parallel procedures warranting RMP updates should be avoided as much as possible.
MAHs are strongly encouraged to streamline RMP amendments and submissions, in co-operation with the EMA for the centrally authorised products, in order to facilitate RMP assessments throughout the product life-cycle.
There are two alternative approaches to the handling of different RMP versions for which the assessment is overlapping, and the MAH should choose the option that facilitates the assessment taking into account anticipated timelines for the finalisation of the procedures.
Whenever separate applications affecting the RMP are submitted in parallel, in order to facilitate the review, it is generally agreed that the MAH initially and whenever appropriate during the procedure submits one joint draft RMP file as a 'working document'. This single RMP document should include all data consequential to the concerned procedures running in parallel . To facilitate the assessment, the proposed RMP changes should be marked (e.g. with different colour code), to differentiate changes specific to each procedure (example: new safety concerns derived from an extension of indication in a new population should be marked differently from the changes in the Pharmacovigilance Plan consequential to (early) termination of a study and initiation of another one as a consequence of the limited safety data gathered in the ended study).
If the parallel applications reach the finalisation stage at the same time, the consolidated RMP version will be adopted by the relevant Committee and will become the approved version of the RMP.
If the applications do not reach the finalisation-stage at the same time, at the time of the first opinion for the parallel procedures, the MAH will need to provide for review and approval a final RMP version including only the agreed changes related to the scope of the variation application for which the CHMP is about to adopt an opinion. The joint RMP 'working document' will continue to be used in the context of the remaining ongoing procedure(s).
Example: A safety variation is triggered whilst an extension of indication procedure is ongoing, both requiring significant changes in the RMP (new safety concern in the new indication; another safety concern and a new imposed PASS in the safety variation). The RMP for the safety variation can be built upon the RMP document submitted with the extension of indication.
Option A: A joint RMP document including changes relevant to both procedures could be submitted with both the responses to the RSI in the extension procedure, and with the initial submission for the safety variation:
- If both procedures reach the Opinion stage at the same time, than the joint RMP will be adopted and become the approved RMP.
- If however the extension of indication requires a second RSI, and is most likely to be finalised after the parallel safety variation, the MAH will then have to submit before the opinion for the safety variation an RMP including only the safety concern and the new study related to the safety variation data. This version of the RMP will be checked for consistency and approved with the safety variation opinion. The updated joint RMP 'working document', including the changes consequential to the responses to the second RSI for the extension of indication will continue to be assessed within the extension of indication procedure. This joint RMP will be considered the approved RMP once the extension of indication variation reaches opinion.
A graphical representation for option A is included below:
Option B: Alternatively, it might be more appropriate when parallel procedures will follow very different assessment timetables to opt for an approach similar to the handling of parallel procedures with product information changes; the RMP submitted with each procedure should only include the changes related to that procedure:
- an updated version of the RMP is submitted as a type II variation to reflect the changes in the safety profile derived from post-marketing reporting. This RMP version should include only the changes related to the RMP update.
- subsequently or at the same time, another RMP update is submitted as part of a type II variation for the extension of indication. For this application, the RMP version only includes the changes that are consequential to the extension of indication (i.e. not the changes related to the safety variation.
If both procedures conclude at the same time, the MAH is expected to merge the two RMP documents for approval by the Opinion time.
If the RMP update variation is approved before the extension of indication procedure, the RMP submitted will be adopted with the relevant changes and the MAH can submit a consolidated RMP version as part of the MAH's responses to an RSI for the extension of indication. This RMP version includes then the changes approved as part of the recently finalised safety variation (as clean text) as well as the changes related to the extension of indication (with track changes).
The option B can be illustrated as follows:
Regardless of the approach chosen, the MAH should always provide a clear description of the scope(s) of the submission in the cover letter and the changes implemented in the RMP including references to related (previous/parallel) regulatory procedure(s) (see also Question 8 below).
Guidance on the format and content of the RMP as outlined in GVP module V and RMP template has been made available in the Pharmacovigilance section of the Agency's website. The submitted RMP should follow the RMP template and guidance.
The RMP should be provided in CTD section 1.8.2. RMP versions submitted for assessment should be version controlled and dated. All parts and modules of the RMP should be submitted in one single PDF-file so that a complete RMP is provided to the Agency.
Only clean versions of documents in PDF format should be managed within the eCTD lifecycle. However, due to the fact that additional formats are required to facilitate the assessment i.e. 'tracked changes' versions for SmPCs, RMPs or other documents as specified by the agency, these should be provided in Word format in the separate folder 'XXXX-working documents'. Further details in this regard can be found in section 2.9.9 of the Harmonised Guidance for eCTD Submissions in the EU. It is generally not necessary to include the annexes as part of the RMP 'working document' unless any of the annexes are actually revised. If no tracked changes version can be compiled (e.g. due to template transition when the tracked changes would be significant throughout the document), a 'clean' Word version file of the RMP should still be submitted in the 'XXXX-working documents' folder; this will facilitate the preparation of the RMP Summary to be published on the Agency website.
In general, any submitted version of the RMP should be based on the latest approved version (i.e. the latest version agreed by CHMP). However, sometimes it may be more appropriate to base the next version to be submitted on the latest RMP 'working document' version, especially when several procedures affecting the RMP are ongoing in parallel (see Question 7 above).
Regardless, the submitted RMP version should be seen as a draft, until approved. Details of the RMP approval status should be provided in the Module I of the document. The revised RMP should always get a new version number every time an updated RMP version is submitted for assessment (see recommendations on document versioning in the Guidance on the format of the risk management plan (RMP) in the EU – in integrated format).
When relevant, a discussion of the proposed RMP changes should be included in the (non-) clinical overview (addendum). It should be noted that the provision of a (non-)clinical overview (addendum) is mandatory as part of a (non-)clinical type II variation application which includes a revised RMP regardless of the fact that there may be no impact on the product information. In this case the (non-) clinical overview (addendum) should discuss and justify the proposed RMP changes. On the other hand, a (non-) clinical overview (addendum) is never required as part of type IA and type IB variation applications.
In the EU application form (AF) and for (non-)clinical variations, the “Present/Proposed” table will in general only reflect proposed changes to the EN Annexes (SmPC, Annex II, labelling and Package Leaflet). It is not foreseen that the updates to the RMP are reflected in the AF in detail unless quite limited in scope. Instead, when comprehensive changes to the RMP are proposed, it is recommended to provide a comparative table of the RMP (latest agreed version vs. proposed version), summarising – for all individual RMP parts and modules – the main updates. For example, all changes linked to the implementation of a new template can be summarised as 'new RMP template'. Such comparative table should be provided as an annex to the AF.
As a matter of principle the day of the CHMP Opinion/EMA Notification is the last opportunity for the MAH to provide an updated version of the RMP (in word format) for agreement. The same RMP version with the same version number – without any additional changes - can thereafter be submitted as part of a formal eCTD closing sequence post-opinion. However, if additional changes to the RMP are identified post-opinion after receipt of the document, an updated RMP version with a new version number should be provided for review as part of a type IB variation under category C.I.11.z.
The same principles apply also in situations when there are different RMP versions undergoing assessment in parallel and concluding the same month (see also Question 7 above). MAHs are requested to provide the final consolidated RMP version (in word format) before the date of the CHMP Opinion/EMA Notification.
The timelines of the progress reports for a given study should be pre-specified and indicated in the protocol. These progress reports may include available interim results, but there is in general no obligation or recommendation to include interim results in PSURs and RMPs unless required as part of an agreed pharmacovigilance plan. This is without prejudice that a variation as appropriate should be submitted should these interim results lead to product information changes or RMP changes.
The PRAC Rapporteur will be involved in the assessment of all variations that include an updated RMP. For type IB variation including RMP, PRAC Rapporteur will be in the lead of the assessment. For type II variations, the CHMP or PRAC may take the lead during the assessment depending on the composition of the data provided, and this will be decided on a case-by-case basis at the time of the EMA validation.
At the time of validation the Agency will inform the MAH of the involvement of the PRAC Rapporteur through the assessment timetable which will refer to the relevant assessment reports expected from the PRAC Rapporteur, as appropriate.
As explained in the hereby questions and answers on RMP, the RMP update can be submitted either as part of a procedure driven by another main change defining the procedure classification (e.g. extension of indication, new formulation, etc.) or as a stand-alone variation exclusively including the RMP. In the latter, the variation can be either a type II, type IB or type IA, see question 'Which variation classification will apply for my RMP updates?' for further guidance.
Irrespective whether the RMP update is consequential to another change or a stand-alone update, the RMP document follows the eCTD life-cycle management and should be provided in Module 1.8.1 of the eCTD structure. Submission of the RMP should be made according to the framework of the procedure to which it belongs to and should follow the requirements and technical process for this procedure. More information is available on ‘Submitting a post-authorisation application’.
The use of the eSubmission Gateway or Web Client is mandatory for all electronic Common Technical Document (eCTD) submissions through the centralised procedure. The European Medicines Agency (EMA) no longer accepts submissions on CD or DVD. This applies to all applications for human medicines.
Depending on the application submission date, either the Revision 1 or the Revision 2 version of the Guidance on format of the risk-management plan in the European Union should be used including for generics. The Rev. 2 version is also applicable to generics as it includes specific guidance to generics. The transitional arrangements for the RMP submission are presented in the table below.
Acceptable template revisions to be used for RMP submissions:
RMP submission with: 01.10.2017 – 30.03.2018 On and after 31.03.2018 Any post-marketing procedure (initial submission or with responses to a RSI)
RMPs submitted using Rev. 1 of the template instead of Rev.2 will not be rejected at validation of the submission, but will automatically trigger an additional step of assessment and an outstanding issue; applicants and MAHs will be required to update the RMP using the Rev.2 of the template and submit it with the responses to the RSI.
All post-authorisation RMP updates using Guidance on the format of the risk management plan (RMP) in the EU – in integrated format (Rev. 2) leading to the RMP Summary update will trigger the publication of the RMP Summary.
The RMP Summary will be reviewed during the procedure under RMP Part VI, and will be approved as part of the agreed RMP.
Post-opinion, the MAH will be asked to extract the RMP summary as a stand-alone PDF document and send it via EudraLink to the EMA. The PDF document should not contain meta-data, headers or footers related to the overall RMP document, nor excessive formatting.
The extracted PDF RMP Summary will be published on the EMA website at the time of the EPAR update, on the product's page (EPAR summary landing page).
- Directive 2001/83/EC
- Regulation (EC) No 726/2004
- Commission implementing Regulation No 520/2012 of 19 June 2012 on the performance of pharmacovigilance activities
- Guideline on good pharmacovigilance practices – Module V – Risk Management Systems (Rev 1)
- RMP template
- European Commission Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures
When the MAH / Applicant for a generic medicinal product submits an RMP for assessment, the safety concerns should be aligned to those of the originator product that are available either from the originator’s approved RMP or from the list of safety concerns of the substance published on the CMDh website. Any divergence introduced in the RMP of the generic product (e.g. new safety concerns) should be thoroughly justified based on either differences in products’ characteristics (e.g. excipients), or on compelling data generated with this generic product that would warrant a difference in the list of safety concerns in the RMP (e.g. clinical trial or post-marketing epidemiological study data). This justification should be detailed in Module SVII of Part II of the RMP.